Traditional and New Approaches to the Management of Immune Thrombocytopenia: Issues of When and Who to Treat

Hematology/Oncology Clinics of North America

Volumn 23, Issue 6, 2009, Pages 1329-1341

  Bussel, James B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Autoimmunity; Bleeding; ITP; Platelets; Thrombocytopenia

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DAPSONE; DEXAMETHASONE; DOXORUBICIN; ELTROMBOPAG; ESTROGEN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; PROTEIN KINASE SYK INHIBITOR; RHESUS D ANTIBODY; RITUXIMAB; ROMIPLOSTIM; VALPROIC ACID; VINCA ALKALOID; VINCRISTINE;

AUTOIMMUNE THROMBOCYTOPENIA; BONE MARROW SUPPRESSION; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; INJECTION SITE REACTION; LABORATORY DIAGNOSIS; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; REMISSION; REPEATED DRUG DOSE; REVIEW; SERUM SICKNESS; SHORT COURSE THERAPY; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 70449629813     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.09.004     Document Type: Review

References (47)

1. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: Report from an International Working Group. Blood 113 11 (2008) 2386-2393
2. Cheng Y., Wong R.S., Soo Y.O., et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349 9 (2003) 831-836
3. Mazzucconi M.G., Fazi P., Bernasconi S., et al. Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 109 4 (2007) 1401-1407
4. Cooper N., Stasi R., Cunningham-Rundles S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenia purpura. Br J Haematol 125 2 (2004) 232-239
5. Cooper N., Woloski B.M.R., Fodero E.M., et al. Does treatment with intermittent infusions of IV anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura (ITP) to avoid splenectomy?. Blood 99 6 (2002) 1922-1927
6. George J.N., Raskob G.E., Vesely S.K., et al. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 74 3 (2003) 161-169
7. Godeau B., Lesage S., Divine M., et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 82 5 (1993) 1415-1421
8. Bussel J., Pham L.C., Aledort L., et al. Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood 72 1 (1988) 121-127
9. Kalpatthi R., and Bussel J.B. Management of refractory immune thrombocytopenic purpura. Curr Opin Pediatr 20 (2008) 8-16
10. McMillan R., Bussel J.B., George J.N., et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 83 2 (2008) 150-154
11. Mathias S.D., Bussel J.B., George J.N., et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 5 (2007) 11
12. George J.N., Mathias S.D., Go R.S., et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 144 3 (2009) 409-415
13. Cheng G., Saleh M.N., Bussel J.B., et al. Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double- blind, placebo-controlled study (RAISE). [ASH Annual Meeting Abstracts]. Blood 112 (2008) 400
14. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. ASH Education. Hematology 2009, in press.
15. Acharya S., and Bussel J.B. Valproate: hematologic toxicities of sodium valproate. J Pediatr Hematol Oncol 22 1 (2000) 62-65
16. Onel K., and Bussel J.B. Adverse effects of estrogen therapy in a subset of women with ITP. J Thromb Haemost 2 4 (2004) 670-671
17. Hymes K.B., Greene J.B., and Karpatkin S. The effect of azidothymidine on HIV-related thrombocytopenia. N Engl J Med 318 8 (1988) 516-517
18. Marks KM, Clarke RMA, Bussel JB, Talal AH, Glesby MJ. Brief report: risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. JAIDS 2009, in press.
19. Rajan S.K., Espina B.M., and Liebman H.A. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol 129 6 (2005) 818-824
20. Stasi R., Sarpatwari A., Segal J.B., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood 113 6 (2009) 1231-1240
21. DiMaggio D., Anderson A., and Bussel J.B. Cytomegalovirus causes refractory immune thrombocytopenic purpura. Br J Haematol 146 1 (2009) 104-112
22. Calleja E., Klein R., and Bussel J. Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-1?. Am J Hematol 61 (1999) 94-97
23. Teachey D.T., Manno C.S., Axsom K.M., et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 105 6 (2005) 2443-2448
24. Rao V.K., Price S., Perkins K., et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer 52 7 (2009) 847-852
25. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 28 Suppl 1 (2008) S42-S45
26. Zhang L., Radigan L., Salzer U., et al. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol 120 (2007) 1178-1185
27. Cines D., and Bussel J. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 106 (2005) 2244-2251
28. Cohen Y.C., Djulbegovic B., Shamai-Lubovitz O., et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160 11 (2000) 1630-1638
29. Portielje J.E., Westendorp R.G., Kluin-Nelemans H.C., et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97 9 (2001) 2549-2554
30. Psaila B., and Bussel J.B. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 143 1 (2008) 16-26
31. Kojouri K., Vesely S.K., Terrell D.R., et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104 9 (2004) 2623-2634
32. Ahn Y.S., Horstman L.L., Jy W., et al. Vascular dementia in patients with immune thrombocytopenic purpura. Thromb Res 107 6 (2002) 337-344
33. Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard J, Bussel JB. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol 2009, in press.
34. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113 20 (2009) 4834-4840
35. Wang J., Wiley J., Luddy R., et al. Chronic immune thrombocytopenia purpura (ITP) in children: assessment of rituximab treatment. J Pediatr 146 2 (2005) 217-221
36. Bussel J.B., Kuter D.J., George J.N., et al. Effect of a novel thrombopoiesis-stimulating protein (AMG 531) in chronic immune thrombocytopenic purpura. N Engl J Med 355 (2006) 1672-1681
37. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 371 (2008) 395-403
38. Bussel J.B., Kuter D., Pullarkat V.A., et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113 10 (2009) 2161-2171
39. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag, an oral platelet growth factor, for the treatment of patients with chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 22 (2007) 2237-2247
40. McHutchison J.G., Dusheiko G., Shiffman M.L., et al. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357 22 (2007) 2227-2236
41. Bussel J.B., Provan D., Shamsi T., et al. During treatment of chronic idiopathic thrombocytopenic purpura (ITP): a randomized, double blind, placebo-controlled study. Lancet 373 9664 (2009) 641-648
42. Berchtold P., and McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 74 7 (1989) 2309-2317
43. Huhn R.D., Fogarty P.F., Nakamura R., et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 101 1 (2003) 71-77
44. Figueroa M., Gehlsen J., Hammond D., et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 328 17 (1993) 1226-1229
45. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med 344 18 (2001) 1402-1403
46. Boruchov D.M., Gururangan S., Driscoll M.C., et al. Multi-agent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 110 10 (2007) 3526-3531
47. Podolanczuk A., Lazarus A.H., Crow A.R., et al. Of mice and men: an open label pilot study for treatment of immune thrombocytopenic purpura (ITP) by an inhibitor of syk. Blood 113 14 (2009) 3154-3160